Quantcast

Latest Genetic disorders Stories

2014-10-21 08:33:06

-- Enrollment in Huntington's Trial Suspended Pending Further Assessment of Preclinical Data -- SEATTLE, Oct. 21, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition. Omeros has...

2014-06-24 10:39:41

Washington University in St. Louis Researchers believe they have learned how mutations in the gene that causes Huntington’s disease kill brain cells, a finding that could open new opportunities for treating the fatal disorder. Scientists first linked the gene to the inherited disease more than 20 years ago. Huntington’s disease affects five to seven people out of every 100,000. Symptoms, which typically begin in middle age, include involuntary jerking movements, disrupted...

2014-06-12 12:26:31

Lack of Disease-Modifying Therapies is Expected to Remain a Critical Unmet Need and Provides Ample Opportunity for Developers, According to Findings from Decision Resources Group BURLINGTON, Mass., June 12, 2014 /PRNewswire/ -- Decision Resources Group finds that three therapies, Teva's Huntexil, Auspex's SD-809 and Raptor's Procysbi, will likely receive regulatory approval for Huntington's disease (HD) in the United States and the EU5 markets (Germany, France, Italy, Spain and United...

2014-05-07 20:24:01

LONDON, May 7, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Genetic Disorders Partnering Terms and Agreementshttp://www.reportbuyer.com/pharma_healthcare/biotechnology/genetic_disorders_partnering_terms_agreements.htmlThe report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.The Genetic Disorders Partnering Terms and Agreements...

2014-03-04 08:32:30

CARDIFF, Calif., March 4, 2014 /PRNewswire/ -- NI Research has released the March issue of NeuroPerspective, which reviews and assesses the range of neurotherapeutics programs in development for Huntington's Disease. Huntington's is a devastating orphan neurodegenerative disorder known to affect approximately 30,000 patients in the United States, with another 150-200,000 individuals genetically at risk for the disease. Recent weeks have seen the release of Phase II trial results in HD...


Latest Genetic disorders Reference Libraries

44_b4e6022f2dde476f8bd4cab961972a2d
2007-12-13 19:44:51

The Munchkin is a fairly new breed of cat with a lot of controversy surrounding it. The breed is created by a mutation that causes achondroplasia, or hypochondroplasia, which results in the cats having abnormally short legs. The breed originated when a pregnant, short-legged black cat was discovered in Louisiana in 1983. One of her kittens, a tomcat, became the father of the breeding program for Munchkins. Several cat registries refuse to recognize the breed due to the controversy that...

More Articles (1 articles) »
Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related